Skip to main content

Table 4 Number and proportion of patients reporting AEs during treatment, for events reported by at least 1% of patients in the FF or placebo arms

From: Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma

Number of patients reporting event, n (%) Placebo
nDPI
(n= 145)
Placebo
DISKUS
(n= 42)
FF
200 μg OD
(n= 140)
FF
100 μg
BD
(n= 142)
FP 200 μg OD
(n= 42)
FP 100 μg BD
(n= 43)
Any on-treatment AE 21 (14) 5 (12) 22 (16) 26 (18) 2 (5) 3 (7)
   URTI 2 (1) 0 7 (5) 7 (5) 0 0
   Sinusitis 0 1 (2) 1 (< 1) 2 (1) 0 0
   Pharyngitis 2 (1) 0 1 (< 1) 0 0 0
   Cellulitis 2 (1) 0 0 0 0 0
   Tooth infection 0 0 2 (1) 0 0 0
   Cough 0 0 0 2 (1) 0 0
   Headache 2 (1) 0 2 (1) 0 0 0
   Tension headache 0 0 2 (1) 0 0 0
  1. Data shown are for the ITT population.
  2. AE = adverse events; BD = twice daily; FF = fluticasone furoate; OD = once daily; URTI = upper respiratory tract infections.